AMENDMENTS TO THE CLAIMS

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Currently Amended) The ~~pharmaceutical composition of claim 1~~individual dosage formulation of claim 17, wherein said first antibody is contained in ~~a dosage range~~ an amount of 0.01 – 41 mg.

8. (Cancelled)

9. (Currently Amended) The method according to claim 820, wherein said ~~pharmaceutical composition~~ first antibody is administered by subcutaneous, intradermal or intramuscular injection.

10. (Canceled)

11. (Cancelled)

12. (Currently Amended) The method of claim 820 or 9 wherein said antibody is administered at a dosage in the range of 0.01 to 41 mg antibody.

PAGE 5/10 * RCVD AT 12/9/2005 4:37:59 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/31 * DNIS:2738300 * CSID:7147088565 * DURATION (mm-ss):02-54

13. (Canceled)

14. (Previously Presented) The method according to claim 12 wherein said dosage is 0.5 mg antibody.

15. (Cancelled)

16. (Cancelled)

17. (Currently Amended) An individual dosage ~~vaccine~~ formulation which comprises 0.01 – 4 mg of an antibody directed against the cellular membrane antigen Ep-CAM and at least one adjuvant useful ~~in the formulation of a vaccine~~ to ~~thereby~~ enhance an immune response, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

18. (Currently Amended) The formulation of claim 17, wherein said adjuvant is at least one member selected from the group consisting of aluminum hydroxide, a lipopolysaccharide derivative, a Bacillus Calmette Guerin liposome preparation, tetanus toxoid, pseudom~~m~~onas exotoxin, an influenza virus, GM-CSF, IL-2 or IFN8.

19. (Previously Presented) The formulation of claim 17, further comprising at least one second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.

20. (Previously Presented) A method of treating cancer disease which comprises administering an effective cancer treatment amount in the range of 0.01–4 mg of a first antibody directed against the cellular membrane antigen Ep-CAM, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO:

PAGE 6/10 * RCVD AT 12/9/2005 4:37:59 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/31 * DNIS:2738300 * CSID:7147088565 * DURATION (mm-ss):02-54

1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

21. (Currently Amended) The method of claim 20, wherein said first antibody is administered in an amount of 0.01–41 mg.

22. (Previously Presented) The method of claim 21, wherein said first antibody is administered in combination with at least one adjuvant useful in the formulation of a vaccine.

23. (Currently Amended) The method of claim 22, wherein said adjuvant is at least one member selected from the group consisting of aluminum hydroxide, a lipopolysaccharide derivative, a Bacillus Calmette Guerin liposome preparation, tetanus toxoid, Pseudomonas exotoxin, an influenza virus, GM-CSF, IL-2 or IFN8.

24. (Previously Presented) The method according to claim 21, wherein said first antibody is administered in combination with at least one second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.

PAGE 7/10 * RCVD AT 12/9/2005 4:37:59 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/31 * DNIS:2738300 * CSID:7147088565 * DURATION (mm-ss):02-54